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Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers and 
overall survival rates have barely improved over the past five decades. The 
antimetabolite gemcitabine remains part of the standard-of-care, but shows very 
limited anti-tumor efficacy. Ataxia telangiectasia and Rad3-related protein (ATR), the 
apical kinase of the intra-S-phase DNA damage response (DDR), plays a central role 
in safeguarding cells from replication stress (RS) and can therefore limit the efficacy 
of antimetabolite drug therapies. We investigated the ability of the ATR inhibitor, 
AZD6738, to prevent the gemcitabine-induced intra-S-phase checkpoint activation 
and evaluated the anti-tumor potential of this combination in vitro and in vivo. In 
PDAC cell lines, AZD6738 inhibited gemcitabine-induced Chk1 activation, prevented 
cell cycle arrest and restrained RRM2 accumulation, leading to the strong induction 
of replication stress markers only with the combination. Moreover, synergistic growth 
inhibition was identified in a panel of 5 mouse and 7 human PDAC cell lines using 
both Bliss Independence and Loewe models. In clonogenic assays, the combination 
abrogated survival at concentrations for which single agents had minor effects. In 
vivo, AZD6738 in combination with gemcitabine was well tolerated and induced 
tumor regression in a subcutaneous allograft model of a KrasG12D; Trp53R172H; Pdx-
Cre (KPC) mouse cancer cell line, significantly extending survival. Remarkably, the 
combination also induced regression of a subgroup of KPC autochthonous tumors, 
which generally do not respond well to conventional chemotherapy. Altogether, our 
data suggest that AZD6738 in combination with gemcitabine merits evaluation in a 




With a mortality rate that nearly matches its incidence rate, pancreatic ductal 
adenocarcinoma (PDAC) is currently the 4th most common cause of cancer-death 
and is projected to become the 2nd leading cause by 2030(1). Late diagnosis, 
metastatic behavior and therapeutic resistance contribute to this poor prognosis and 
a 5-year survival rate of <8%. The antimetabolite gemcitabine, a nucleoside 
analogue that induces replication-associated DNA damage, was the first drug 
approved for this disease. In recent years, two combinations have been approved 
after showing significant benefit in clinical trials, FOLFIRINOX (folinic acid, 
fluorouracil, irinotecan, and oxaliplatin) and Nab-paclitaxel in combination with 
gemcitabine, but median survival remains less than 12 months for patients with 
PDAC(2,3). Also, both are cytotoxic-based therapies that many patients cannot 
tolerate. Intrinsic and acquired resistance limit the efficacy of these non-specific 
therapies and warrant the search for better, more targeted options. 
Targeting the replication stress (RS) response is of particular interest because it has 
the potential to specifically kill cancer cells as well as enhance sensitivity to 
chemotherapies(4). Indeed, RS, which can be broadly defined as the perturbation of 
replication fork progression and stalling during S-phase, has emerged in recent 
years as one of the hallmarks of cancer(5). Although RS is inherent to DNA 
synthesis and can therefore affect normal replicative cells, it is particularly elevated 
in cancer cells for two reasons.  First, the imposed and unrestrained proliferation 
underlying carcinogenesis greatly challenges the highly ordered nature of DNA 
replication, increasing reliance on RS pathways. Second, increased mutagenic 
exposure to extrinsic factors or by altered DNA repair mechanisms, which are 
common routes to transformation, result in DNA lesions impeding DNA synthesis. 
Reciprocally, persistent RS is thought to fuel genomic instability(6). 
The need to tolerate high levels of RS is of particular relevance to PDAC biology. 
Indeed, canonical genetic alterations observed in human PDAC converge to promote 
cell cycle entry through KRAS activating mutations (90%), MYC amplification (14%), 
cyclins D and E amplification (40%), while G1/S cell cycle checkpoints are abrogated 
by deletion or inactivating mutation of tumor suppressor genes such as TP53 (75%) 
and CDKN2A (46%)(7-9). Besides alterations in canonical pathways, large scale 
sequencing efforts have recently uncovered the high frequency (>35% of cases) of 
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mutations affecting DDR genes and their association with poor outcome in PDAC(9). 
This is in line with germline mutations in some DDR genes promoting familial 
pancreatic cancers and known interactions between altered DDR pathways and 
mutagenic exposure increasing the risk of developing PDAC(10). In addition, the 
high degree of genome instability frequently observed in PDAC is arguably a 
signature of an underlying defect in repair genes(11). Importantly, while loss of 
certain DDR components participates in generating high levels of RS, it also confers 
vulnerabilities in the form of synthetic lethality. 
ATR is the apical kinase of the replication checkpoint and plays a critical role in 
safeguarding genome integrity from RS(4,5,12). ATR achieves this by inhibiting 
origin firing, preventing replication fork collapse and favoring the repair and restart of 
damaged forks. The global effect of ATR activation on cell cycle progression is 
mediated by its downstream target Chk1, leading to inhibition of Cdk2 in S-phase 
and of Cdk1 in G2. Meanwhile local effects are mediated by regulation of fork-
repair/fork-remodeling proteins. In addition, ATR activation also helps sustain DNA 
synthesis by increasing dNTP pools through ribonucleotide reductase M2 (RRM2) 
upregulation(13,14). Activation of several oncogenes plus the inactivation of many 
tumor suppressors has been found to confer sensitivity to ATR inhibitors(15). 
Furthermore, because the RS response is an intrinsic resistance mechanism to 
chemotherapy, targeting the pathway is a promising strategy to sensitize cancer cells 
to cytotoxic drugs. Indeed, ATR inhibition has been shown to increase sensitivity to 
gemcitabine and radiation in vitro(16-18). Moreover, targeting Chk1, the downstream 
ATR effector has been shown to enhance gemcitabine anti-tumor activity in vitro and  
in vivo(19,20). 
We describe the evaluation of the sensitivity of a panel of pancreatic cancer cell lines 
to the ATR inhibitor, AZD6738 (U.S. patent No. US 8,552,004 B2, Example 2.02) 
(21,22), alone or in combination with gemcitabine. We also investigated the ability of 
low concentrations of gemcitabine to sensitize cells to AZD6738, including the most 
resistant cell lines, and characterized the features and mechanisms of the apparent 
synergy. Finally, our in vivo studies demonstrate the anti-tumor effect of AZD6738 in 
combination with gemcitabine and provide a rational for a clinical trial to treat 
patients with PDAC. 
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MATERIALS AND METHODS 
 
Cell culture and chemicals 
Human pancreatic cancer cells (MIA PaCa-2, Panc-1, SW1990, Capan-1, AsPC-1, 
HPAF-II, Capan-2), were obtained from either the European Collection of Cell 
Cultures or the ATCC. They were authenticated using either Promega GenePrint10 
System or Promega PowerPlex 16HS kit and were grown in DMEM with 10% FBS 
(GIBCO). Murine pancreatic cancer cells K8484, DT8082, TB31456, TB32048 were 
previously established from  KRasG12D; p53R172H; Pdx1-Cre mice and were grown in 
DMEM with 10% FBS(23). KPCFT79653 was from a KrasG12D; Trp53R270H; 
Brca2Tr/11; Pdx-Cre (KPCB) mouse(24). All cell lines were grown up to a maximum 
of 20 passages and for fewer than 6 months following resuscitation. They were 
routinely verified to be mycoplasma-free using the Mycoprobe Mycoplasma 
Detection Kit (R&D Systems). Gemcitabine hydrochloride (Tocris), AZD6738 
(AstraZeneca), were dissolved in DMSO, kept at -20°C, and used within 3 months. 
Final DMSO concentrations (0.2%) were kept constant in all experiments. Yoyo-3 
(Life Technologies) was used at a final concentration of 0.1 mM. 
 
SRB assay 
Cells were grown in 96-well plates in their respective conditions for 72 or 120 hours. 
Medium was then aspirated and the cells washed once with phosphate-buffered 
saline (PBS), before the addition of 100 µL of 3% trichloroacetic acid (TCA) to each 
well. Following incubation at 4°C for 1 hour, the TCA was removed and each well 
was washed once with 100 µL of cold water. 50 µL of 0.057% Sulforhodamine B 
solution (Sigma-Aldrich, #230162-5G) in 1% acetic acid was added to each well to 
allow staining at room temperature for 30 minutes. Plates were rinsed four times with 
1% acetic acid using an automated plate washer (Biotek Elx405 Select CW). After 
drying, 200 µL of 10 mM Tris base solution (pH 10.5) was added to each well and 
the solubilisation of protein-bound dye was achieved by placing plates on a gyratory 
shaker for 5 minutes. The SRB signal was measured at excitation and emission 
wavelengths of 488 nm and 585 nm respectively, using a PHERAstar FS plate 
reader (BMG Labtech). The fluorometric signal values were used as surrogates for 
cell number. Pharmacological growth rate inhibition was assessed using the GR 
metrics R package developed by Clark et al., 2017 (www.grcalculator.org). The 
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metrics were based on a calculation that compares the cell number at the start and 
at the end of the assay in the absence of drug, to that in the presence of drug. This 
calculated a ratio between growth rates under treated and untreated conditions, 
normalized to a single doubling(25,26). 
 
Clonogenic assay 
Cells were plated at 300 cells/well in 6-well plates 5 hours prior to treatment. After 24 
hours of treatment, the medium was replaced and the cells left to grow for 8 more 
days after the washout. Cells were then fixed and stained with SRB (as above). 
Colonies were imaged and quantified using the GelCount (Oxford Optronix). Plating 
efficiency was calculated from the ratio of the number of colonies to the number of 
cells seeded. The number of colonies that arose after treatment was expressed as 
surviving fraction. This was derived from the ratio of the number of colonies formed 
after treatment to the number of cells seeded multiplied by plating efficiency of the 
control. 
 
IncuCyte time lapse imaging 
Images were acquired with the IncuCyte Live Cell Imaging microscopy (Essen 
Bioscience) at every 3 hours under cell culture conditions with 10 objective. 
Averaged cell confluence was calculated from 3 random fields of view per well using 
the IncuCyte in-built algorithm. Cell death was measured by adding YOYO™-3 
Iodide cell-impermeant dye to appropriate medium. 
 
AZD6738 PK modeling 
In vivo AZD6738 pharmaco-kinetics were simulated with the following standard two-
compartmental model, reproducing gut, central, and peripheral clearance(27). 
𝑑𝐺𝑈𝑇
𝑑𝑡
=  −𝑘𝑎𝐺𝑈𝑇  
𝑑𝐶𝐸𝑁
𝑑𝑡


















Model parameters are the ones reported(27) and drug concentration in the plasma is 
given by 𝐶𝑝 =
𝐶𝐸𝑁
𝑉1
. Simulations of AZD6738 dynamics were performed using the 
commercial software Matlab. 
Immunostaining and immunoblotting 
For immunostaining, cells were fixed with 4% paraformaldehyde, permeabilized with 
0.3% Triton X-100, stained with antibodies, and counterstained with 4’,6-diamidino-2-
phenylindole (DAPI). For immunoblotting, whole cell extracts were obtained by lysis 
in 50mM Tris-HCl PH7.5, 2% SDS, protease inhibitor, phosphatase inhibitors. 
Proteins were resolved using the SDS-PAGE gel system (Life Technologies). Blots 
were imaged and analyzed using the Odyssey Infrared Imaging System (LI-COR). 
 
Antibodies 
Primary antibodies used were from Cell Signalling unless otherwise mentioned: β-
actin (Abcam #ab6276), cleaved PARP (#5625), CDK1 Y15 (#9111), CHK1 (#2360), 
CHK1 S345 (#2348), H2AX (#7631), H2AX S139 (Millipore #05-636), H3 (#9715), 
H3 S10 (#3377), RRM2 (ABNOVA #H00006241-M01), ATR (Santa Cruz #1887), 
ATR T1989 (Gene Tex #GTX128145), CHK2 (#2662), CHK2 T68 (Abcam #3501), 
KAP1 (Abcam #10484), KAP1 S824 (Abcam #133440), DNA-PKcs (Abcam #70250), 
DNA-PKcs S2056 (Abcam #18192), ATM (Abcam #78), ATM S1981 (Abcam 
#81292), RPA32 (Abcam #2175), RPA32 S4/8 (Bethyl Laboratories #A300-245A), 
RPA32 S33 (Bethyl Laboratories #A300-246A).  
For secondary antibodies, Alexa 488 (#4408, #4412) and Alexa 647 (#4410, #4414) 
from Cell Signalling were used in immunostaining. IRDye800-conjugated (#925-
32210, #926-33210) and IR680-conjugated (#926-68070, #926-68021) antibodies 
from LICOR were used in immunoblotting.  
 
In vivo studies 
All mouse experiments were carried out in the CRUK Cambridge Institute BRU, in 
accordance with the UK Animals (Scientific Procedures) Act 1986, with approval 
from the CRUK Cambridge Institute Animal Ethical Review and Welfare Body. 
Subcutaneous allografts of K8484 cells were conceived by implanting 106 cells in 
PBS, in the right flank of 7-12-week old female PC mice. For efficacy study, mice 
with established tumor (Average 374 mm3) were randomized and treated 
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accordingly. Gemcitabine (LKT Laboratories, from Cambridge Bioscience) was 
dissolved in a saline solution (Vetivex) at 20 mg/mL and given to mice at 100 mg/kg 
intraperitoneally. AZD6738 (AstraZeneca) was dissolved at 2.5 mg/mL in 10% 
DMSO, 40% Propylene Glycol, 50% de-ionized sterile water and given to mice at 25 
mg/kg by oral gavage. 
PDAC was detected via ultrasound in KPC mice using a Vevo2100 imaging system 
(Visual Sonics, Toronto, Canada). Mice with 3 to 6 mm tumors were recruited for the 
efficacy study. Tumor diameter at each time point in the KPC study was calculated in 
a blinded manner using Vevo 2100 v1.5.0 by viewing ultrasound scans of the tumour 
in 3D mode, identifying in the z plane the widest part of the tumour then measuring 
the longest diameter at that point.   
 
Quantitative fluorescence-based microscopy 
Fixed and immuno-fluorescently labelled cells were imaged using the iCys laser 
scanning cytometer (CompuCyte) (40X objective). Analytical data were generated 
using the iCys Cytometric Analysis Software based on the acquired images. 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded sections were immunostained after heat-induced 
epitope retrieval by sodium citrate at 100°C for 10-20 minutes, using Bond Polymer 
Refine Detection kit on the automated Bond system according to manufacturer’s 
instructions (Leica). Slides were mounted using Leica CV5030 Coverslipper 
Workstation and scanned using a ScanScopeXT (Aperio Technologies). 




Genetic alterations driving RS in PDAC and sensitivity to AZD6738 
A number of studies, in various experimental settings in vitro and in vivo, have 
identified genetic alterations that increase the sensitivity to either downregulation or 
inhibition of ATR(15,28-33). We sought to interrogate this expanding list of genes, 
with respect to the frequency of their alteration in the complex genomic landscape of 
PDAC. For this purpose we explored the TCGA cohort using cBioPortal 
(http://www.cbioportal.org), also interrogating the database for alterations in genes 
likely to increase RS. Our analyses revealed that ~93% of PDAC samples exhibit at 
least one genetic alteration likely to sensitize to ATR inhibition (4% only one, 21% 
two and 68% three or more), validating this pathway as a potential therapeutic target 
(Fig. 1A).  
We next assessed the growth inhibitory effect of AZD6738, a novel ATR inhibitor, 
using the SRB assay(34). In order to capture some of the genetic heterogeneity 
observed in PDAC, we tested AZD6738 in a panel of seven human cell lines 
(Supplementary Table 1), four lines from the KrasG12D; Trp53R172H; Pdx-Cre (KPC) 
mouse(35) and one line from a KrasG12D; Trp53R270H; Brca2Tr/11; Pdx-Cre (KPCB) 
mouse(24). The growth rate (GR) metrics R package developed by Clarke et al. 
(www.grcalculator.org), was used to generate normalized GR inhibition values, thus 
controlling for the different doubling times of the cell lines(25,26). We observed that 
the 4 lines from the KPC model were very sensitive to AZD6738 with a 
submicromolar GR50, in line with our data mining (Fig. 1B). This degree of sensitivity 
has been shown to confer anti-tumor efficacy to AZD6738 monotherapy in human 
LoVo colorectal adenocarcinoma xenografts(21,36). Three of the human lines, 
SW1990 (GR50=0.94 M), Capan-1 (GR50=1.57 M) and AsPC-1 (GR50=1.98 M), 
showed moderate sensitivity (Fig. 1C). Four human cell lines, HPAF-II 
(GR50=3.2M), Capan-2 (GR50=4.8M), MiaPaCa-2 (GR50=9.8M), Panc-1 
(GR50=32.3M) and the mouse line KPCFT79653 (GR50=2.6M) from the KPCB 
model, exhibited various degrees of resistance. 
As even for the most sensitive lines, GR90 values ranged from 1.4 M (TB32048) to 
1.97M (SW1990), we reasoned that achieving anti-tumor efficacy in vivo using 
AZD6738 monotherapy, would be unlikely for the majority of PDAC. Therefore, we 
sought to utilize gemcitabine to increase RS to sensitize PDAC cell lines to AZD6738 
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and also to overcome intrinsic gemcitabine resistance. Low concentrations of 
gemcitabine greatly reduced the GR50 of all cell lines, particularly the more resistant 
lines, demonstrating sensitization to AZD6738 by gemcitabine (Fig 1D, E). 
 
AZD6738 prevents the checkpoint activation elicited by gemcitabine 
We next investigated whether AZD6738 could counteract the checkpoint activation 
elicited by gemcitabine. Importantly, in K8484 cells, AZD6738 at 2 µM completely 
prevented gemcitabine-induced Chk1 phosphorylation on Serine 345, the 
downstream ATR target (Fig. 2A). AZD6738 abrogated gemcitabine-induced 
inhibition of Cdk1, assessed by the inhibitory tyrosine 15 phosphorylation, and 
restored the mitotic marker Histone H3 phospho-Serine10 to normal levels (Fig. 2A). 
Finally, AZD6738 could prevent accumulation of RRM2 induced by gemcitabine (Fig. 
2A). In the five mouse cell lines, AZD6738 at 0.5 M also prevented gemcitabine-
induced Chk1 phosphorylation on Ser345, leading to a strong induction of DNA 
damage, as visualized by H2AX (Supplementary Fig.S1A). We also observed a 
potent abrogation of gemcitabine-induced Chk1 activation in the sensitive human 
lines SW1990 and AsPC-1(Supplementary Fig.S1B, C). We next explored the 
pathway abrogation by AZD6738 in the more AZD6738-resistant lines, MiaPaCa-2 
and Panc-1. Although partial inhibition of the gemcitabine-induced checkpoint 
activation was detectable using AZD6738 at 0.5 M, we found that a higher 
concentration was necessary to fully block the pathway in both cell lines (FIG. 2B 
and Supplementary Fig.S1D). To explore if the need for higher concentrations of 
AZD6738 was due to compensatory pathway activation in these cells, as opposed to 
lack of ATR target engagement, we probed for ATM and DNA-PK activation. We 
found that the combination of AZD6738 + gemcitabine strongly activated ATM 
downstream effectors, pChk2-Threonine 68, and pKap1-Serine 824, as well as auto-
phosphorylation site Serine 1981 (Fig. 2C, D). DNA-PKcs phosphorylation on Serine 
2056 was also strongly induced, only by the combination (Fig. 2C). Phosphorylation 
of RPA on S4/8, a consensus site for DNA-PK was also activated, plus S33 which is 
a consensus site for ATR, ATM, DNA-PK(37) (Fig. 2D) 
This potent activation of ATM and DNA-PK by the combination strongly suggested 
an efficient ‘on target’ inhibition of ATR by AZD6738, and attempts by the cells to 
compensate. In order to confirm this hypothesis, we knocked-down ATM using 
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siRNA in MiaPaCa-2 and repeated the drug exposures (Fig. 2D). Interestingly, 
gemcitabine-induced phosphorylation of ATR on Threonine 1989 was completely 
prevented by AZD6738 at 2 M, only in the ATM knockdown condition (Fig. 2D, red 
dotted boxes). This suggested that the phosphorylation of Threonine 1989 on ATR in 
the presence of the combination was arising through ATM activity (ATM likely being 
activated as a consequence of fork collapse), and not through ATR auto-
phosphorylation. This strongly indicated that AZD6738 at 2 µM was sufficient to 
completely prevent ATR activation.  
We then assessed the RS generated by the combination. In MiaPaCa-2 and Panc-1, 
only the combination induced a strong phosphorylation of pRPA and H2AX, 
indicating a strong induction of RS in these cells (Fig. 2E)(38). We could also detect 
apoptosis through cleaved PARP-1 in MiaPaCa-2, only with the combination, 
indicating induction of apoptosis even as early as 30h after drug exposure.
 
AZD6738 and gemcitabine synergize to inhibit cell growth 
In order to analyze the degree of growth inhibition induced by the combination and 
identify areas of synergy across a wide range of concentrations, we used the SRB 
assay and calculated Loewe and Bliss drug synergy scores using Combenefit 
software(39). We identified areas of synergy in the 7 human and the 5 mouse PDAC 
cell lines (Fig. 3A and Supplementary Fig. S2). We used Metrics available within 
Combenefit to summarize and compare the features of synergy across the different 
cell lines (Table 1).  As expected, the sum of synergy and antagonism was positive 
for all cell lines, attesting the overall synergy. Importantly, both the Loewe and the 
Bliss models similarly ranked the combination across the cell lines. Due to the 
differential sensitivity to single agents between mouse and human cells, we used 2 
different concentration ranges, precluding direct comparison between the two 
species in the Metrics analyses. While few differences appeared in the mouse cells, 
it is noteworthy that Panc-1 cells, very resistant to both drugs alone, exhibited the 
highest degree and extent of synergy and were successfully sensitized by the 
combination. Similarly, the combination displayed high levels of synergy in MiaPaCa-
2 cells. In contrast with the variability in the overall amount of synergy, the 
distribution of the observed synergy in the concentration space was relatively similar. 
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To gain more resolution in the synergy area for MiaPaCa-2, we narrowed the range 
of concentration around the most intense region of synergy. In addition, instead of 
using constant drug exposure, we washed out the drugs after 24h and followed cell 
proliferation by time-lapse microscopy. Profound synergy and durable growth 
inhibition was achieved across the full range of concentrations even with only 24 
hour of drugs (Fig. 3B). Remarkably, total growth inhibition was obtained with the 
combination of 1.5uM AZD6738 and 20nM gemcitabine for 24h, while single agents 
had no effect at these concentrations. At these concentrations and higher, growth 
inhibition was total and maintained for at least 3 days after the washout and cell 
death, measured by YoYo-3 dye entry, increased in parallel (Fig. 3C).  
In order to confirm the synergy between AZD6738 and gemcitabine in a different 
assay system, we used the clonogenic survival assay where the cells were exposed 
to the drugs for 24h before washout. We also found potent synergy and a profound 
reduction in the surviving fraction when combining both drugs in MiaPaCa-2 and 
Panc-1 (Fig. 3D). Intriguingly, we observed emergence of clones even at the highest 
concentrations that we used. This suggests that it might be relevant to repeat or 
increase frequency of treatment in a clinical setting, as well as identify potential 
mechanisms of resistance. 
 
Scheduling of the AZD6738 + gemcitabine combination 
To gain insights into the best scheduling of the combination for subsequent in vivo 
efficacy, we tested sequential versus concurrent drug treatment in the four cell lines 
derived from the KPC model. We used drugs at the GI50 for each cell line and 
followed proliferation. Treating the cells for 16 hours with gemcitabine at GI50 
concentrations had no impact on proliferation (Fig 4A). Treating the cells first with 
gemcitabine for 16 hours and replacing with AZD6738 had a modest effect. In 
contrast, the concurrent treatment of both drugs for 16h resulted in a profound and 
durable growth inhibition. Moreover, maintaining AZD6738 after the first concurrent 
treatment prevented the slow regrowth for at least 3 days. Mechanistically, we found 
that maintaining ATR inhibition after removal of gemcitabine increased the 
persistence of DNA damage (Fig. 4B). In order to translate these findings in vivo and 
optimize a tolerated dose/schedule for the combination, we employed in silico 
modelling of AZD6738 mouse pharmacokinetics (PK)(27). Guided by these 
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simulations, we identified a dose/schedule predicted to sustain 136 hours of plasma 
[AZD6738]>1uM/week (Fig 4C).  
AZD6738/gemcitabine combination shows anti-tumor efficacy in vivo 
We next tested the efficacy and tolerability of this regimen in a four-arm study using 
the K8484 allograft model. All mice in the vehicle and AZD6738 (25 mg/kg x 5 
days/week) single agent groups reached the maximum permitted tumor size before 
the end of the first three weeks of treatment. Gemcitabine (100 mg/kg x 2/week) was 
active as a single agent (as previously published(40)), and controlled tumor growth 
during the initial 3 weeks of treatment (Fig. 5A). However, none of the tumors shrank 
with gemcitabine alone (Fig.5B). In contrast, confirming the in vitro findings, 
combination of gemcitabine with AZD6738 was more efficacious, causing tumor 
shrinkage by the end of week 2 in 6/10 mice and 7/10 mice by the end of week 3. 
During a one week break in treatment, all tumors treated with gemcitabine alone 
regrew rapidly, and although treatment was resumed, most of the tumors reached 
the maximum permitted size, 2/10 remaining just below that threshold (Fig. 5C). One 
animal with a small tumor in the combination group was killed because of ill health 
during the ‘drug holiday’. In the combination group, tumors regrew during the break, 
but at a slower rate, allowing a further 3 weeks of treatment, leading to tumor 
shrinkage in 7/8 (one had completely resolved in the first 3 weeks) remaining mice 
(Fig. 5C), greatly extending survival (Fig 5D). Intriguingly, one tumor had resolved in 
the first three weeks of treatment and remained undetectable till the end. Importantly, 
the drug combination was tolerated without weight loss for the duration of the study, 
suggesting limited toxicity (Fig. 5E). In addition, H2AX staining was elevated in the 
tumors of the mice treated with either single agent gemcitabine or the combination, 
but not in the tumors of the mice treated with single agent AZD6738, in line with the 
anti-tumor effects (Fig. 5F). Thus, the combination of gemcitabine + AZD6738 
showed greater efficacy in this allograft model than gemcitabine alone. 
An efficacy study in the autochthonous KRAS G12D; p53 R172H; Pdx-cre (KPC) mouse 
model was then performed, according to the schedule in Figure 6A. Tumor growth 
was stabilized in 4/10 mice treated for 12 days with AZD6738 + gemcitabine (Fig. 
6B). Remarkably, 3/10 tumors shrank, 2 by more than 10%. This effect was greater 
than with gemcitabine alone, which stabilized the growth of only 2/18 tumors (‘stable 
tumors’ defined as a tumor growth <10% during the 12-days treatment). KPC tumor 
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regression has been very rarely seen historically. If the probability to observe a 
stable disease in the combination group is the same as in the gemcitabine single 
agent group (i.e. 2/18), we would expect to observe 4 or more stable diseases out of 
10 animals only 1.84% of the time (P=0.0184). These data suggest that there may 
be a subset of KPC mice with tumors responsive to the AZD6738 + gemcitabine 
combination. Staining of the tumors for the pharmacodynamic biomarker H2AX 
revealed a strong increase in the gemcitabine and combination groups in  




In recent years, signaling pathways activated by RS, one of the hallmarks of cancer, 
have attracted a lot of attention as therapeutic targets. Potent and selective small-
molecule inhibitors of the apical kinase of the RS response, ATR, are now in early 
phase clinical trials. However, how to rationally combine ATR inhibition with 
genotoxic therapies and which genetic alterations truly confer sensitivity, are 
important questions that remain to be fully answered. Recent reports have 
demonstrated the causal role of certain oncogenic activation and/or tumor 
suppressor inactivation in increasing sensitivity to ATR inhibition. In addition, a 
number of studies have described synthetic lethality relationships with ATR, mostly 
involving alterations in DDR pathways(15,29,31,33,41-47). The most prominent 
genetic alterations found in PDAC (KRAS, TP53, SMAD4, ARID1A) have all been 
shown to increase sensitivity to ATR inhibition. In addition, among the long tail of 
less frequent mutations uncovered by recent studies, mutations in DDR genes are 
found at the highest frequency(9). Therefore, there is an urgent need to assess the 
utility of ATR inhibition in PDAC. In the present study, we explored whether the ATR 
inhibitor AZD6738, could be used to inhibit the growth of PDAC, alone or in 
combination with the antimetabolite gemcitabine, which remains a cornerstone for 
the treatment of patients with all stages of the disease. The results of this study 
demonstrate the improved anti-tumor effect of the combination compared to 
gemcitabine alone and warrant clinical investigation. 
 
ATR is an essential protein and its absence is lethal both at the cellular and 
organismal level, although a profound downregulation is compatible with life(48-50). 
Early studies in yeast revealed that the lethality induced by Mec1 (ATR) ablation was 
due to fatal decrease in ribonucleotide reductase expression(13). The function of 
ATR in maintaining sufficient dNTP levels appears to be conserved in mammalian 
cells(14). In addition, lethality of ATR inhibition in cancer cells has also been shown 
to be the result of premature mitotic entry(51), or global exhaustion of the ssDNA 
binding protein RPA leading to replication catastrophe(52). In the present study we 
observed that 5 out of 12 pancreatic cancer cell lines were very sensitive to 
AZD6738 monotherapy. Interestingly, sub-GI50 levels of gemcitabine potently 
sensitized even the most resistant cell lines to AZD6738. Gemcitabine could 
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sensitize to ATR inhibitors by elevating RS through at least two mechanisms. First, 
by poisoning the DNA polymerase and RRM2, further reducing nucleotide pools to 
compromise DNA synthesis. Second, by inducing DNA lesions, either due to 
dFdCTP incorporation or other misincorporations driven by nucleotide shortage. 
These lesions further increase the reliance on ATR during S-phase, driving RPA 
exhaustion upon ATR inhibition. Reciprocally, we observed that AZD6738 sensitized 
to gemcitabine by at least three mechanisms. Firstly, by preventing the cell cycle 
arrest that would otherwise antagonize gemcitabine incorporation and permit DNA 
repair. Secondly, by promoting fork collapse, through blocking restart or repair of 
damaged forks. And thirdly, by limiting endogenous dNTP pools competing with 
gemcitabine – this can occur through RRM2 downregulation as well as through the 
increase of unscheduled origin firing which further exhausts nucleotides. By 
providing evidence of replication checkpoint inhibition, generation of DSB and 
prevention of RRM2 upregulation, our results suggest that AZD6738 and 
gemcitabine synergize at several molecular levels.   
 
In addition to overcoming inherent gemcitabine resistance mechanisms, ATR 
inhibition could potentially limit acquired resistance to gemcitabine. Indeed, a recent 
study revealed the reliance of gemcitabine-resistant cells on de novo pyrimidine 
synthesis(53). Importantly, in this study the authors did not find evidence of 
increased cytidine deaminase as a mechanism of acquired gemcitabine resistance 
and resistant cells were still capable of gemcitabine uptake. Therefore, combined 
action of RRM2 irreversible inhibition by gemcitabine metabolite dFdCDP and 
downregulation by AZD6738, could potentially help sustain favorable ratio of 
dFdCTP/dCTP needed to maintain efficacy. Accordingly, we found that AZD6738 
restored gemcitabine sensitivity in intrinsically gemcitabine-resistant cells (e.g. 
AsPC-1 and PANC-1). This is also in line with our findings showing sustained 
efficacy of the combination over a period of 6-weeks treatment in vivo. However, 
other mechanisms of resistance to gemcitabine could still curtail the efficacy of the 
combination. The intriguing effect of the combination in our KPC study, showing 
‘responders’ and ‘non responders’, could therefore reflect an intrinsic mechanism of 
gemcitabine resistance in the tumors that did not respond. 
Low level of CDC25A has been found to confer resistance to ATR inhibition as 
monotherapy(51). However, the absence of toxicity in cells expressing low levels of 
18 
 
CDC25A appeared to be due to the absence of premature entry into mitosis. 
Importantly the increased incorporation of EdU upon ATR inhibition was not affected 
by levels of CDC25A. Similarly, dFdCTP incorporation should not be affected, hence, 
combining gemcitabine with ATR inhibition could potentially overcome the resistance 
conferred by CDC25A deficiency. 
We observed that the combination of AZD6738 + gemcitabine strongly induced ATM 
and DNA-PK activation. This is consistent with the role of ATR in preventing fork 
collapse and DSB-response. It is noteworthy that these kinases are members of the 
same family and display substantial promiscuity towards substrates (e.g. H2AX, p-
RPA). For example, DNA-PK can phosphorylate Chk1 independently of ATR, 
indicating that pChk1 is not the most appropriate biomarker for detection of target 
inhibition by AZD6738, especially as cell death and durable growth inhibition was 
achieved at doses lower than that required for maximal inhibition of pChk1-
Ser345(14). ATM and HR repair factors are the first recruited components to 
collapsed forks, generating ssDNA that continue to exhaust RPA pools and push 
cells toward replication catastrophe(54). DNA-PK instead is recruited to the 
damaged forks generated by new origin firing. Therefore, the strong activation of 
DNA-PK by the combination of gemcitabine and AZD6738, indicates an increase in 
origin firing, strongly suggesting on-target ATR inhibition. Moreover, increased levels 
of DNA-PKcs has been shown to confer sensitivity to ATR inhibitor monotherapy(15). 
Therefore, although we cannot exclude compensatory roles for ATM and DNA-PKcs 
activation, our data suggest that activation of both kinases further propagates the RS 
induced by AZD6738 in combination with gemcitabine. 
 
KPC tumor regression has been very rarely seen historically. Our data suggest that 
there may be a subset of KPC mice with tumors responsive to the combination of 
AZD6738 with gemcitabine. A number of genetic alterations have been reported in 
the literature to have synthetic lethal relationships with ATR inhibition, raising the 
possibility of an underlying genetic vulnerability in the responsive tumors. While it will 
be essential to gain insights into the mechanisms underlying responsiveness or 
resistance and possibly identify predictive biomarkers, this work suggests immediate 
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 5 11 8 4 8 6 11 32 21 0.80 0.62 0.71 
 
TB32048 710 355 11 22 17 9 15 12 23 37 30 0.80 0.79 0.79 
 
DT8082 763 395 0 8 4 0 5 3 23 23 23 0.52 0.66 0.59 
 
TB31456 771 359 13 31 22 9 19 14 29 66 47 0.69 0.70 0.69 
 



















SW1990 935 14 56 13 35 23 2 13 23 24 24 1.61 1.27 1.44 
 
Capan-1 1572 21 65 31 48 36 16 26 35 35 35 1.52 1.28 1.40 
 
ASPC1 1983 691 51 31 41 24 13 18 29 26 27 1.43 1.32 1.38 
 
HPAFII 3239 427 90 39 64 39 12 25 38 21 29 1.62 1.57 1.60 
 
Capan-2 4775 2208 62 57 60 12 10 11 33 33 33 1.52 1.48 1.50 
 
MiaPaCa-2 9844 854 91 85 88 57 49 53 52 60 56 1.37 1.23 1.30 
 
Panc-1 >30000 3496 166 135 151 96 74 85 61 57 59 1.76 1.65 1.71 
 
                  
Table 1. Summary of AZD6738 sensitivity and synergy with gemcitabine across the panel of PDAC cell lines. 
GR50 for all cell lines were obtained using the GR metrics R package (developed by Clarke et al., 2017). Mouse and human lines 
are ranked by increasing GR50 for AZD6738. Summing of synergy and antagonism was employed to compare combinations using 
Metrics obtained from Combenefit. Both Bliss, Loewe models and the average (AVG) is shown. SUM_SYN_ANT is the sum of 
synergy and antagonism observed in concentration logarithmic space. For instance, an integrated synergy of 50 is equivalent to an 
extra synergistic effect of 50% which is spread over a square of 1 log x 1 log in the 2-d log-concentration space. Both antagonistic 
and synergistic effects are considered in this metric. The integrated weighted synergy SUM_SYN_ANT_WEIGHTED incorporates a 
weight based on the dose response which bias the total score towards synergy achieving highest effect. Hence, a synergy of 50% 
leading to a combined full effect (100%) will have more weight than if the corresponding effect was only 20 or 30%. Both 
antagonistic and synergistic effects are considered in this metric. SYN_MAX is the maximum level of synergy observed. 





Figure 1. PDAC sensitivity to AZD6738 monotherapy. 
A, Frequency of alterations in genes reported to confer sensitivity to ATR inhibition, 
from the TCGA cohort of PDAC samples (http://www.cbioportal.org). B, C, human 
(B) and mouse (C) PDAC cell lines were grown in increasing concentrations of 
AZD6738 for 3 days to generate dose response curves using the SRB assay. The 
GR metrics R package (developed by Clarke et al., 2017) was used to generate 
normalized growth rate inhibition (GR) values, thus controlling for the different 
doubling times of the cell lines. Drug concentrations that bring the GR value to zero 
are cytostatic, while negative GR values represent cytotoxicity. Each point 
represents the mean of three independent experiments, +/- SEM. D, E, Comparison 
of GR50s for AZD6738 alone or in combination with low dose of gemcitabine (5 nM 
for the most sensitive mouse PDAC lines (D) or 10 nM for KPCFT79653 and human 
lines (E)). Data are represented as mean +/- SEM. Multiple t-tests were performed 
and statistical significance determined using the Holm-Sidak method **p≤0.01, 
***p≤0.001, ns p>0.05. 
 
Figure 2. AZD6738 abrogates the gemcitabine-induced checkpoint activation. 
A, Western blotting for K8484 cells treated as indicated for 7 hours. B, Western 
blotting for MiaPaCa-2 cells treated as indicated for 24 hours. C, Western blotting for 
MiaPaCa-2 and Panc-1 cells treated as indicated for 30 hours. D, MiaPaCa-2 cells 
were treated with scramble or ATM-specific siRNA. After 24h cells were treated as 
indicated for 24h and lysates were immunoblotted. E, Western blotting for MiaPaCa-
2 and Panc-1 cells treated as indicated for 30 hours. Arrowheads indicate the bands 
of interest. Note that the upper band in the pChk1-S345 blots appearing in lysates of 
MiaPaCa-2 treated with the combination is most likely the result of a cross-reaction 
with p-Chk2. 
 
Figure 3. AZD6738 and gemcitabine synergistically inhibit cell growth in a panel of 
PDAC cell lines. 
A, MiaPaCa-2 and Panc-1 cells were treated with AZD6738 and gemcitabine in an 
8x8 concentration grid for 72 hours. Cell viability was determined by measuring the 
total protein content using the sulforhodamine B assay. The experimental data (left, 
values are percentage growth inhibition compared with control) were analyzed 
independently with the two synergy models (Bliss and Loewe) using the Combenefit 
software. Data, mean +/- SD, n = 3. B, C, MiaPaCa-2 cells were treated with 
AZD6738 and gemcitabine in an 6x8 concentration grid for 24 hours. The drugs were 
washed out and replaced with fresh medium containing the YOYO™-3 Iodide cell-
impermeant dye to follow cell death. Three random fields per sample were imaged 
by time lapse microscopy every 3 hours for 4 days. Cell growth was analyzed using 
cell confluency data and expressed as percentage of growth inhibition compared 
with control (B, left panel) and Combenefit software for synergy analyses (B, 2 right 
panels). Growth curves (C, left panel) and cell death accumulation (C, right panel) 
from control cells or cells treated with indicated concentrations of AZD6738 and 
gemcitabine. Data, mean +/- SEM, n = 2. D, Clonogenic survival of Panc-1 and 
MiaPaCa-2 cells plated at very low density and exposed to the indicated drug 
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combinations for 24 hours before washout. Cells were left to grow for 8 days after 
washout. Data, mean +/- SD, n = 3.  
 
Figure 4.  Scheduling of the combination of AZD6738 with gemcitabine. 
A, Four cell lines from the KPC mouse model were plated at low density and treated 
with the first condition for 16 hours, then the medium was replaced with the second 
condition and cell growth was monitored by time lapse microscopy every 3 hours for 
4 days. Drugs were used at the GI50 (72h) concentrations. B, Cells were incubated 
with 10 nM gemcitabine for 16h, then fixed at the time point shown after washout into 
fresh medium or with 300 nM ATRi. Immunofluorescence followed by quantitative 
microscopy was realized to obtain the percentage of cells positive for H2AX. C, 
Dose-schedule schematic (left) of the in silico modelling of AZD6738 mouse PK for 
the gut, circulating and peripheral compartments (right). 
 
Figure 5.  The combination of AZD6738 + gemcitabine achieves anti-tumor effect and 
improves survival, in a subcutaneous allograft of a KPC cancer cell line. 
A, Tumor volume of K8484 allografts. Ten mice per group were treated as indicated 
in the legend (middle of the figure) for 3 consecutive weekly cycles (see 
dose/schedule schematic in Fig.4 C). After a one week break, treatment was 
resumed for another 3 weeks. Data are represented as mean ± SEM. + Culled 
animals. B, Changes in individual tumor volume between D14 and D25 (when all 
mice were still alive). C, Changes in individual tumor volume between D46 and D60 
(only two mice remaining in the gemcitabine alone group). D, Kaplan-Meier survival 
curves. E, Body weight change relative to pre-treatment body weight. Data are 
represented as mean ± SEM. F, Quantification of H2AX-positive cells from tumors 
IHC. Data are represented as mean ± SD. A one-way ANOVA analysis with Tukey’s 
pairwise comparisons was performed, **p≤0.01, ****p≤0.0001, ns p>0.05. 
 
Figure 6.  The combination of AZD6738 + gemcitabine induces tumor regression in a 
subgroup of KPC tumors. 
A, Schematic of the study and dosing schedule. B, Changes in individual tumor long 
diameter between Day -1 and Day 12. Dotted lines represent the mean of each 
group. A one-way ANOVA analysis was performed with Tukey’s pairwise 
comparisons, **p≤0.01, ns p>0.05. During the 12-day study, in the gemcitabine alone 
group, two mice had a ‘stable’ (<10% diameter change) disease, while 16 had a 
‘progressive’ (>10% diameter change) disease. In the combination group, four mice 
had a stable disease, while six had a progressive disease. If the probability to have a 
stable disease in the combination group is the same as in the gemcitabine alone 
group (i.e. 2/18), we would expect to observe 4 or more stable disease out of 10 
animals only 1.84% of the time (p=0.018). C, Quantification of H2AX-positive cells 
from tumors IHC. Data are represented as mean ± SD. A one-way ANOVA analysis 
with Tukey’s pairwise comparisons was performed, ***p≤0.001. 






